费城染色体
微小残留病
PDGFRB公司
CD19
Blinatumoab公司
流式细胞术
癌症研究
分子生物学
生物
淋巴细胞白血病
白血病
基因
免疫学
遗传学
染色体易位
作者
Han Lin,Lu Chen,Ruoyao Huang,Shufang Xue,Gaoyuan Sun,Chengyi Wang,Shuhong Shen,Hui Zhang,Yongzhi Zheng
标识
DOI:10.1097/fpc.0000000000000554
摘要
Based on driver mutations and gene expression profiles, the International Consensus Classification currently divided the entity ‘Philadelphia chromosome-positive (Ph + ) B-cell precursor acute lymphoblastic leukemia (ALL)’ into two subtypes: lymphoid-only and multilineage involvement (Ph + ALL-L and -M, respectively). The similar biological characteristics of Ph-like ALL and Ph + ALL drove us to assume that Ph-like ALL-M subtypes exist. This report presents two pediatric ALL cases (one Ph + and one Ph-like) with minimal residual disease negativity established by multicolor flow cytometry but persistent transcript detection by quantitative PCR (qPCR) even after second-line treatment with tyrosine kinase inhibitors combined with blinatumomab immunotherapy. Using droplet digital PCR, BCR::ABL1 or TPM3::PDGFRB transcripts were identified in CD19 + cells as well as in non-CD19 + cells, suggesting the presence of a Ph + or Ph -like ALL-M subtype originating from hematopoietic stem cells. This report provides information for better characterization, diagnosis, and treatment of these ALL subtypes.
科研通智能强力驱动
Strongly Powered by AbleSci AI